MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer

American Journal of Roentgenology

Volumn 190, Issue 5, 2008, Pages 1180-1186

  Kim, Chan Kyo ^a   Byung, Kwan Park ^a   Hyun, Moo Lee ^a   Sam, Soo Kim ^b   Kim, EunJu ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kangwon National University College of Medicine   (South Korea)

^c PHILIPS HEALTHCARE   (United States)

Author keywords

Diffusion weighted MRI; Dynamic contrast enhanced MRI; High intensity focused ultrasonic ablation; Localized prostate cancer; MRI

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 43649096576     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2924     Document Type: Article

References (35)

1. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48:546-551
2. Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999; 161:163-168
3. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999; 17:517-522
4. Aus G. Current status of HIFU and cryotherapy in prostate cancer: a review. Eur Urol 2006; 50:927-934
5. Ragde H, Blasko JC, Grimm PD, et al. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Semin Surg Oncol 1997; 13:438-443
6. Poissonnier L, Chapelon JY, Rouviere O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007; 51:381-387
7. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60:3-11
8. Huber P, Debus J, Jenne J, et al. Therapeutic ultrasound in tumor therapy: principles, applications and new developments [in German]. Radiologe 1996; 36:64-71
9. Colombel M, Gelet A. Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 2004; 7:289-294
10. Rebillard X, Gelet A, Davin JL, et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol 2005; 19:693-701
11. Gelet A, Chapelon JY, Poissonnier L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004; 63:625-629
12. Rouviere O, Mege-Lechevallier F, Chapelon JY, et al. Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 2006; 50:490-497
13. Rouviere O, Lyonnet D, Raudrant A, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001; 40:265-274
14. Susani M, Madersbacher S, Kratzik C, Vingers L, Marberger M. Morphology of tissue destruction induced by focused ultrasound. Eur Urol 1993; 23[suppl 1]:34-38
15. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 2001; 13:607-614
16. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 2006; 30:7-11
17. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229:248-254
18. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience. Radiology 2004; 233:709-715
19. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161:401-407
20. Kim CK, Park BK, Han JJ, Kang TW, Lee HM. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr 2007; 31:449-454
21. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 Tesla. Invest Radiol 2006; 41:185-188
22. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006; 23:130-134
23. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005; 235:728-739
24. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22: 639-646
25. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237:541-549
26. Carriere KC, Roos LL, Dover DC. Across time and space: variations in hospital use during Canadian health reform. Health Serv Res 2000; 35:467-487
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174
28. Gelet A, Chapelon JY, Bouvier R, et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996; 29:174-183
29. Thuroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003; 17:673-677
30. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004; 63:297-300
31. Chaussy C, Thuroff S, Rebillard X, Gelet A. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005; 2:191-198
32. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006; 97:56-61
33. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006; 98:537-539
34. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000; 89:1800-1809
35. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006; 9:439-443